Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | bone morphogenetic protein 1b | 0.0071 | 0.5 | 0.5 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.0071 | 0.5 | 0.5 |
Echinococcus granulosus | laminin | 0.0071 | 0.5 | 0.5 |
Echinococcus multilocularis | laminin | 0.0071 | 0.5 | 0.5 |
Schistosoma mansoni | subfamily M12A unassigned peptidase (M12 family) | 0.0071 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0071 | 0.5 | 0.5 |
Loa Loa (eye worm) | low-density lipoprotein receptor repeat class B containing protein | 0.0071 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0071 | 0.5 | 0.5 |
Brugia malayi | Fibulin-1 precursor | 0.0071 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0071 | 0.5 | 0.5 |
Loa Loa (eye worm) | multiple epidermal growth factor-like domains 6 | 0.0071 | 0.5 | 0.5 |
Brugia malayi | Low-density lipoprotein receptor repeat class B containing protein | 0.0071 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0071 | 0.5 | 0.5 |
Schistosoma mansoni | egf-like domain protein | 0.0071 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0071 | 0.5 | 0.5 |
Echinococcus multilocularis | Tolloid protein 1 | 0.0071 | 0.5 | 0.5 |
Echinococcus multilocularis | fibrillin 1 | 0.0071 | 0.5 | 0.5 |
Onchocerca volvulus | Arrow homolog | 0.0071 | 0.5 | 0.5 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.0071 | 0.5 | 0.5 |
Echinococcus granulosus | Tolloid protein 1 | 0.0071 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | > 100 uM | Displacement of [3H]-pirenzepine from cerebral Muscarinic acetylcholine receptor M1 | ChEMBL. | No reference |
IC50 (binding) | > 100 uM | Displacement of [3H]-pirenzepine from cerebral Muscarinic acetylcholine receptor M1 | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.